Management of Hypertension in Hemodialysis Patients

Primary Treatment Approach

The American College of Cardiology recommends achieving dry weight through adequate ultrafiltration and enforcing dietary sodium restriction as the cornerstone of treatment for hypertension in hemodialysis patients, with a target predialysis blood pressure of 140/90 mmHg 1, 2, 3

Beta-blockers demonstrate the strongest mortality benefit in dialysis patients and should be preferred for patients with previous myocardial infarction or established coronary artery disease, according to the American Heart Association 1, 3
The American College of Cardiology recommends using calcium channel blockers, such as amlodipine, as first-line therapy for hemodialysis patients with hypertension who lack specific cardiovascular indications for beta-blockers 1, 3

ACE inhibitors/ARBs may reduce left ventricular mass index and preserve residual kidney function in hemodialysis patients, according to the National Kidney Foundation 1, 2, 3
The American Journal of Kidney Diseases states that ACE inhibitors/ARBs should be used with caution in hemodialysis patients due to the increased risk of hyperkalemia 4

The American Journal of Kidney Diseases recommends avoiding combination therapy with ACE inhibitors and ARBs due to increased risks of hyperkalemia and acute kidney injury 4
The Kidney International journal suggests monitoring serum potassium frequently when using ACE inhibitors/ARBs in hemodialysis patients 5, 6

The treatment algorithm for hemodialysis patients with hypertension involves optimizing volume status, using beta-blockers or calcium channel blockers as first-line therapy, and adding ACE inhibitors/ARBs as second-line agents if necessary, according to the American College of Cardiology 1, 2, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines note that fosinopril did not reduce cardiovascular events and death compared with placebo in hemodialysis patients with left ventricular hypertrophy, and ARB trials have shown inconsistent results for cardiovascular outcomes, highlighting the need for careful selection of antihypertensive agents in this population 7, 8
Atenolol showed fewer heart failure hospitalizations compared to the ACE inhibitor lisinopril in hemodialysis patients with hypertension and left ventricular hypertrophy, suggesting that beta-blockers may be preferred in certain cases 7, 8
Calcium channel blockers, such as amlodipine, reduced cardiovascular events compared with placebo in hemodialysis patients with hypertension and should be considered as first-line therapy for patients without specific cardiovascular indications for beta-blockers 7, 8

For patients with significant residual kidney function, ACE inhibitors or ARBs are particularly beneficial and should be preferred, as they slow the decline in residual kidney function, according to the American Journal of Kidney Diseases 9, 10
Ramipril preserved approximately 1 mL/min greater GFR at one year, and valsartan slowed GFR and urine volume decline at 24 months in peritoneal dialysis patients, demonstrating the renoprotective effects of these agents 9, 10

Avoid combination therapy with ACE inhibitors and ARBs, as this increases risks of hyperkalemia and acute kidney injury without improving outcomes, as noted in Diabetes Care 11
ACE inhibitors should be used with caution in hemodialysis patients due to increased risk of hyperkalemia, and serum potassium should be monitored frequently when using these agents 11